Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disparity in the application of guideline-based medical therapy after percutaneous coronary intervention: analysis from the Japanese prospective multicenter registry.
Endo A, Kohsaka S, Miyata H, Kawamura A, Noma S, Suzuki M, Koyama T, Ishikawa S, Momiyama Y, Nakagawa S, Sueyoshi K, Takagi S, Takahashi T, Sato Y, Ogawa S, Fukuda K. Endo A, et al. Among authors: takagi s. Am J Cardiovasc Drugs. 2013 Apr;13(2):103-12. doi: 10.1007/s40256-013-0021-8. Am J Cardiovasc Drugs. 2013. PMID: 23585142
Comparison between working day and holiday acute coronary syndrome presentation.
Mogi S, Kohsaka S, Miyata H, Kawamura A, Noma S, Suzuki M, Koyama T, Ishikawa S, Momiyama Y, Nakagawa S, Sueyoshi K, Takagi S, Takahashi T, Takamoto S, Ogawa S, Sato Y, Fukuda K; JCD-KICS Investigators. Mogi S, et al. Among authors: takagi s. Int J Cardiol. 2011 Nov 17;153(1):85-7. doi: 10.1016/j.ijcard.2011.08.075. Epub 2011 Sep 19. Int J Cardiol. 2011. PMID: 21937132 No abstract available.
Busulfan conditioning and prognostic impact of jaundice in late-onset sinusoidal obstruction syndrome following allogeneic hematopoietic cell transplantation.
Takagi S, Watanabe O, Yamaguchi K, Kageyama K, Kaji D, Taya Y, Nishida A, Ishiwata K, Yamamoto H, Asano-Mori Y, Yamamoto G, Wake A, Taniguchi S, Uchida N. Takagi S, et al. Bone Marrow Transplant. 2024 Dec 23. doi: 10.1038/s41409-024-02501-1. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39715812 No abstract available.
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Lancet. 2024 Dec 17:S0140-6736(24)01927-5. doi: 10.1016/S0140-6736(24)01927-5. Online ahead of print. Lancet. 2024. PMID: 39706209
Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma.
Takagi S, Nakajima M, Koike S, Takami M, Sugiura Y, Sakata S, Baba S, Takemoto A, Huang T, Seto Y, Saito M, Funauchi Y, Ae K, Takeuchi K, Fujita N, Katayama R. Takagi S, et al. Oncogene. 2024 Dec 11. doi: 10.1038/s41388-024-03251-6. Online ahead of print. Oncogene. 2024. PMID: 39663392
2,107 results